“The Terasaki Institute leads the world in the development of bioprintable, biopolymer-based technologies poised to revolutionize drug delivery, wearable and implantable devices. Jointly with HTL we expect to bring to life a new generation of biopolymer-based applications in critical sectors of precision and regenerative medicine,” added Maurizio Vecchione, Chief Innovation Officer of the Terasaki Institute for Biomedical Innovation.
Read more below.
To see our most recent news,
Read more
news from us
-
Press releases May 6, 2024
Acquisition of the Modern Meadow’s human recombinant collagen platform for beauty and biomedical applications
HTL Biotechnology strengthens its position as a global leader in the production and development of pharmaceutical-grade biopolymers by acquiring the beauty and biomedical division of American company Modern Meadow (Nutley, NJ). Notably, this acquisition includes Modern Meadow’s platform of recombinant proteins, with the most advanced product being human recombinant collagen type III (rhCOL3).
-
Articles April 16, 2024
HTL Biotechnology at In-cosmetics Global Congress in Paris
As every year, the In-Cosmetics Global Congress returns to Paris, with top industry leaders and experts gathering under one roof.
This event promises opportunities and insights into the future of Cosmetics. -
Articles April 9, 2024
France BioLead Membership
France BioLead structures, pilots, supports and promotes the French biomanufacturing sector.